TheraVida, Inc.

News

May 16, 2011 TheraVida Initiates Phase 2 Trial of THVD-201 for Overactive Bladder and Urinary Incontinence; Multi-national Study to be Conducted by Novotech in Australia, New Zealand, and South Korea
MOUNTAIN VIEW, California, and SYDNEY, Australia, May 16, 2011 /PRNewswire-iReach/ -- TheraVida, Inc., a clinical stage biopharmaceutical company developing novel combination drug products, announced the start of a Phase 2 clinical trial of its lead product candidate THVD-201 for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI). Read more.

March 21, 2011 TheraVida Announces Positive Results from a Phase 1 Trial of THVD-201 for Overactive Bladder at the 2011 Annual Congress of the European Association of Urology; Product Safety Profile and Improvements in Dry Mouth Side Effect Support Future Phase 2 Studies

March 21, 2011 /PRNewswire/ -- MOUNTAIN VIEW, Calif., TheraVida, Inc., a clinical stage biopharmaceutical company developing novel combination drug products, today presented positive results from a Phase 1 clinical trial of its lead product candidate THVD-201 for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI). In this Phase 1 study, 17 healthy subjects receiving THVD-201 exhibited no significant safety issues related to the product. Meanwhile, subjects in this study did demonstrate major improvements in their salivary output and related dry mouth side effects when receiving THVD-201, as compared to standard anti-muscarinic (tolterodine) therapy for overactive bladder. This data was presented at the 2011 Annual Congress of the European Association of Urology (EAU) in Vienna, Austria Full Text

January 1, 2011 LifeScienceLeader. Biopharm Business Development:
Biotech Innovation And Access To Capital In An Era Of Reform by Gail Dutton
Click to read Full Text.